Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial

BACKGROUND AND OBJECTIVE: Most evidence suggests that the pharmacokinetics of monoclonal antibodies (mAbs) are not meaningfully altered by patient characteristics, including racial/ethnic differences. Nevertheless, the pharmacokinetic profile of eptinezumab has not been evaluated in a Chinese popula...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xue-Ning, Xu, Hong-Rong, Cui, Ellen, Petersen, Kamilla Buchberg, Ryding, Janka, Ettrup, Anders, Østergaard, Jette Buch, Larsen, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632206/
https://www.ncbi.nlm.nih.gov/pubmed/37917246
http://dx.doi.org/10.1007/s40261-023-01315-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632206/
https://www.ncbi.nlm.nih.gov/pubmed/37917246
http://dx.doi.org/10.1007/s40261-023-01315-1

Ejemplares similares